Ticker Details
Cue Biopharma, Inc. Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
IPO Date:	January 2, 2018
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$123.74M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.32 | 4.53%
Avg Daily Range (30 D):	$2.50 | 11.89%
Avg Daily Range (90 D):	$0.98 | 10.69%

Institutional Daily Volume
Avg Daily Volume:	.54M
Avg Daily Volume (30 D):	.99M
Avg Daily Volume (90 D):	6.61M

Trade Size
Avg Trade Size (Sh.):	215
Avg Trade Size (Sh.) (30 D):	38
Avg Trade Size (Sh.) (90 D):	385

Institutional Trades
Total Institutional Trades:	189
Avg Institutional Trade:	$2.12M
Avg Institutional Trade (30 D):	$.95M
Avg Institutional Trade (90 D):	$.95M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.17M
Avg Closing Trade (30 D):	$.81M
Avg Closing Trade (90 D):	$.81M
Avg Closing Volume:	8.48K

News

May 7, 2026 @ 11:07 PM Cue Biopharma Reports Inducement Grants Under Nasd... Source: Na

Apr 8, 2026 @ 12:00 PM Cue Biopharma to Receive $7.5 Million Preclinical ... Source: Na

Jul 23, 2025 @ 1:26 PM High‑Growth Oncology Market Projected For U... Source: Prnewswire

Jun 24, 2025 @ 8:48 PM Cue Biopharma Receives FDA Feedback on Pre-IND Bri... Source: N/A

Apr 15, 2025 @ 2:23 AM Cue Biopharma Announces Pricing of Approximately $... Source: Globe Newswire

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-1.21	$-1.08	$.03
Diluted EPS	$-1.21	$-1.08	$.03
Revenue	$32.73M	$5.69M	$21.94M
Gross Profit
Net Income / Loss	$-19.52M	$-5.18M	$1.59M
Operating Income / Loss	$-19.61M	$-5.35M	$1.98M
Cost of Revenue
Net Cash Flow	$3.24M	$-10.76M	$15.44M
PE Ratio

Splits
Apr 24, 2026	1:30